Skip to content
AnalystLens

West Pharmaceutical Services 8-K Report, Financial Results (Feb 13, 2025)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed February 13, 2025
Period End
February 13, 2025
Security
WST
In the record · 2016–202610-K1110-Q338-K118

WST filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Feb ’18Feb ’18
  2. Leadership change8-K · May ’20May ’20
  3. Leadership change8-K · Jul ’22Jul ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 13, 2025. Cited figures are marked; the original filing is the authoritative source.

West Pharmaceutical Services, Inc. (NYSE: WST) furnished an 8-K on February 13, 2025 reporting fourth-quarter and full-year 2024 results and introducing 2025 guidance.

Fourth-quarter 2024 net sales were $748.8 milliona, up 2.3%, with organic net sales growth of 3.3%, a return to positive organic growth as destocking moderated. Reported-diluted EPS was $1.78, down 2.7%, and adjusted-diluted EPS was $1.82, down 0.5%. Proprietary Products net sales rose to $613.9 million in the quarter with organic growth of 4.5%, while Contract-Manufactured Products net sales declined 2.5% to $134.9 million.

For full-year 2024, net sales were $2.893 billionb, down 1.9% (organic down 1.5%). Reported-diluted EPS was $6.69, down 15.1%, and adjusted-diluted EPS was $6.75, down 16.5%. Operating cash flow was $653.4 million, down 15.9%, and free cash flow was $276.4 million, down 33.3%.

The company repurchased 1,583,032 shares for $560.9 millionc during 2024. For 2025, management guided to net sales of $2.875 billion to $2.905 billion, organic growth of approximately 2% to 3%, and adjusted-diluted EPS of $6.00 to $6.20, which excludes potential stock-based compensation tax benefits.

Capital spending is expected to be $275 milliond. The guidance includes a $75 million foreign currency headwind to net sales and an approximately $0.23 EPS headwind from currency.

02—Key points

Key Highlights

  1. Q4 2024 net sales of $748.8 million rose 2.3%, with organic growth of 3.3%, marking a return to positive organic growth as destocking moderated.
  2. Proprietary Products Q4 net sales reached $613.9 million with 4.5% organic growth; High-Value Products represented approximately 74% of segment net sales.
  3. Q4 Proprietary Products sales included a benefit of approximately $25 million in customer incentives tied to HVP Delivery Device volumes.
  4. Full-year 2024 reported-diluted EPS of $6.69 declined 15.1%; adjusted-diluted EPS of $6.75 declined 16.5%.
  5. Full-year 2024 free cash flow was $276.4 million, down 33.3%, as operating cash flow fell to $653.4 million and capital expenditures rose to $377.0 million.
  6. 2025 guidance calls for net sales of $2.875 billion to $2.905 billion and adjusted-diluted EPS of $6.00 to $6.20, with capital spending of $275 million.
  7. Company repurchased 1,583,032 shares for $560.9 million in 2024 at an average price of $354.30.

03—Questions

Frequently Asked Questions

  1. Did West Pharmaceutical return to organic growth in the fourth quarter of 2024?

    Yes. Fourth-quarter 2024 organic net sales grew 3.3%, and management described it as a return to positive organic growth as the impact of destocking continued to moderate. Proprietary Products organic net sales increased 4.5%, while Contract-Manufactured Products organic net sales declined 2.0%.

  2. What is the 2025 earnings outlook?

    The company expects 2025 adjusted-diluted EPS of $6.00 to $6.20, compared with reported 2024 adjusted-diluted EPS of $6.75. The range includes an estimated headwind of approximately $0.23 from foreign currency and assumes a tax rate of approximately 22%. It excludes potential 2025 tax benefits from stock-based compensation, which would be a positive adjustment if realized.

  3. What are the main drivers of the 2025 outlook?

    Management pointed to improving High-Value Products trends in Biologics and Generics, growth from Annex 1 adoption and GLP-1 demand, and continued momentum in key Proprietary Products areas. Organic net sales growth is expected to be approximately 2% to 3%, and net sales guidance includes an estimated $75 million foreign currency headwind.

  4. How did cash generation and capital spending trend in 2024?

    Operating cash flow was $653.4 million, down 15.9% from the prior year, while capital expenditures rose 4.1% to $377.0 million. Free cash flow fell 33.3% to $276.4 million. Management planned 2025 capital spending of $275 million, including capacity expansions at existing HVP sites and Contract Manufacturing investments.

  5. How did the company return capital to shareholders in 2024?

    West repurchased 1,583,032 shares for $560.9 million during 2024 at an average share price of $354.30 under its share repurchase program. Cash and cash equivalents ended the year at $484.6 million, down from $853.9 million at December 31, 2023.

04—Continue

← View all 8-K filings